Verve Therapeutics (VERV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on the stock and has a $21.00 price target.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Cory Jubinville, PhD has given his Buy rating due to a combination of factors, primarily focusing on the promising safety and efficacy profile of Verve Therapeutics’ VERVE-102. The initial Phase 1b data from the Heart-2 study indicates that VERVE-102 is well-tolerated with no treatment-related serious adverse events, cardiovascular issues, or significant changes in liver function tests or platelet levels. This positive safety profile is attributed to the shift in lipid nanoparticle composition from VERVE-101 to VERVE-102, which has shown to be more favorable.
In terms of efficacy, VERVE-102 has demonstrated competitive LDL-C reductions, with results ranging from 41% to 59% depending on the dosage. These reductions are on par with, or even exceed, those achieved by current PCSK9 inhibitors. The data supports the potential for advancing to a more robust Phase 2 study, reinforcing the confidence in Verve Therapeutics’ approach and justifying the Buy rating.